Related Experiment Videos
CPC-211 (Questcor)
1Department of Pharmacology and Therapeutics, Seth GS Medical College, Parel, Mumbai 400 012, India. mthatte@bom5.vsnl.net.in
Idrugs : the Investigational Drugs Journal
|August 13, 2005
Summary
CPC-211 shows promise for treating stroke and head injuries by reducing brain lactate levels. This drug stimulates pyruvate dehydrogenase, converting lactate into a beneficial metabolite and protecting brain tissue.
Area of Science:
- Neurology
- Pharmacology
Background:
- CPC-211 is an investigational drug developed by Questcor for neurological conditions.
- Stroke and closed head injury are significant causes of brain damage often associated with lactic acidosis.
Purpose of the Study:
- To evaluate the efficacy of CPC-211 in preclinical models of stroke and head injury.
- To assess CPC-211's mechanism of action in reducing brain lactate levels.
Main Methods:
- Preclinical studies were conducted using stroke and head injury models.
- CPC-211 was administered intravenously at doses ranging from 25 to 200 mg/kg.
- Brain lactate levels were measured to assess the drug's effect.
Main Results:
- CPC-211 demonstrated a significant reduction in brain lactate levels in both stroke and head injury models.
- The drug stimulates pyruvate dehydrogenase, promoting lactate conversion to acetyl-CoA.
- CPC-211 is capable of crossing the blood-brain barrier.
Conclusions:
- CPC-211 exhibits neuroprotective potential by mitigating lactic acidosis in the brain.
- The drug's mechanism involves enhancing lactate metabolism, suggesting therapeutic value for acute brain injuries.